ASCLF - Supply enters ritonavir tablets supply agreement with Simcere
- Ascletis Pharma ( OTCPK:ASCLF ) subsidiary Ascletis Pharmaceuticals enters a supply agreement of ritonavir tablets with Hainan Simcere Pharmaceutical, a subsidiary of Simcere Pharmaceutical Group.
- Ascletis currently owns the only authorized ritonavir oral tablet in China, which has passed bioequivalence study.
- Ritonavir tablet is a pharmacokinetic booster of multiple oral antiviral protease inhibitors.
For further details see:
Supply enters ritonavir tablets supply agreement with Simcere